Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$14 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-2.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
6.1
Industry P/E
--
EV/EBITDA
-3.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.7
Face value
--
Shares outstanding
23,481,600
CFO
$-29.69 Mln
EBITDA
$-50.02 Mln
Net Profit
$-49.88 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Acurx Pharmaceuticals LLC (ACXP)
| -22.8 | 57.1 | 48.4 | -73.0 | -43.8 | -- | -- |
|
BSE Sensex*
| 5.6 | 1.1 | 6.0 | 6.8 | 16.2 | 18.8 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
Acurx Pharmaceuticals LLC (ACXP)
| -78.5 | -3.8 | -7.9 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Acurx Pharmaceuticals LLC (ACXP)
|
0.6 | 14.2 | 0.0 | -11.9 | -- | -1 | -- | 6.1 |
| 50.0 | 7,821.1 | 1,208.8 | 131.7 | 13.4 | 6.3 | 60.1 | 3.9 | |
| 128.3 | 8,303.1 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 148.4 | 7,238.7 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 51.2 | 9,911.0 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 45.7 | 11,827.4 | 2,298.9 | 643.6 | 35.4 | 29.2 | 19.8 | 5.2 | |
| 53.9 | 6,506.1 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14 | 13.5 | |
| 315.3 | 8,891.5 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.6 | 15.0 | |
| 26.8 | 9,927.7 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 128.2 | 12,449.9 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.8 | 4.9 |
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the... polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York. Address: 259 Liberty Avenue, Staten Island, NY, United States, 10305 Read more
Co-Founder & Executive Chairman
Mr. Robert J. DeLuccia
Co-Founder & Executive Chairman
Mr. Robert J. DeLuccia
Headquarters
Staten Island, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Acurx Pharmaceuticals LLC (ACXP) stood at $ 7 Mln as on 31-Mar-25
The share price of Acurx Pharmaceuticals LLC (ACXP) is $0.63 (NASDAQ) as of 24-Jun-2025 16:27 EDT. Acurx Pharmaceuticals LLC (ACXP) has given a return of -43.85% in the last 3 years.
Acurx Pharmaceuticals LLC (ACXP) has a market capitalisation of $ 14 Mln as on 24-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Acurx Pharmaceuticals LLC (ACXP) is 6.12 times as on 24-Jun-2025, a 119% premium to its peers’ median range of 2.79 times.
Since, TTM earnings of Acurx Pharmaceuticals LLC (ACXP) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Acurx Pharmaceuticals LLC (ACXP) and enter the required number of quantities and click on buy to purchase the shares of Acurx Pharmaceuticals LLC (ACXP).
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York. Address: 259 Liberty Avenue, Staten Island, NY, United States, 10305
The CEO & director of Mr. Robert J. DeLuccia. is Acurx Pharmaceuticals LLC (ACXP), and CFO & Sr. VP is Mr. Robert J. DeLuccia.
There is no promoter pledging in Acurx Pharmaceuticals LLC (ACXP).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,260
|
|
|
1,128
|
|
|
991
|
|
|
988
|
|
|
870
|
|
|
829
|
|
|
809
|
|
|
742
|
|
|
664
|
| Acurx Pharmaceuticals LLC (ACXP) | Ratios |
|---|---|
|
Return on equity(%)
|
-1.03
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Acurx Pharmaceuticals LLC (ACXP) was $0 Mln.
$0.03
(
